PRINCETON JUNCTION, N.J., July 10 /PRNewswire/ -- Lutronic, Inc., one of the world's leading developers and manufacturers of aesthetic and medical laser systems, announced today that it has received regulatory clearance from the U.S. FDA (Food and Drug Administration) for the eCO2 system.
Using the proprietary Controlled Chaos Technology (CCT), this next-generation fractional CO2 laser is designed to offer a safe and innovative way to treat deep ablative indications such as resurfacing and coagulation of soft tissue, textural irregularities, fine lines, pigmented lesions, vascular dyschromia, and rhytides. The eCO2 has several features that offer customizable treatments that are easy to use and less painful to the patients.
Dr. J. David Holcomb, immediate past president of the Florida Society of Facial Plastic Surgeons, states that "the eCO2 is a familiar wavelength in an extremely elegant and versatile package, with the ability to perform incisional surgery, traditional ablative resurfacing and ablative microfractional photothermolysis."
Of particular interest to users is the ability to combine two operational modes in one delivery system, which is important when deep penetration and greater patient comfort is required. With both Static and Dynamic operation modes, users have the capability to stamp up to a 14x14mm scan area as well as the option to "feather" the treatment area to reduce the "checkerboard" appearance that is common with currently available fractional CO2 devices.
Further, at a 120 micron spot size, initial biopsy studies indicate that the laser can penetrate as deep as 2.4mm into the dermis. "We are seeing long-lasting and consistent results after just one treatment with the eCO2 system. Preliminary results show that patients may not need a follow-up treatment," says Jhung Won Hwang, Ph.D., Sr. Director, Regulatory Affairs, Lutronic, Inc.
With several international and U.S. patents pending, the eCO2 has added multifunctional features, including an intuitive software that can select between a random or sequential beam pattern, as well as a built-in skin sensor technology that prevents the laser from firing unless the handpiece tip is in contact with the skin. A wide range of indications may be treated with its 3 different treatment tip sizes, including a point beam tip for traditional CO2 excision and vaporization of tissue-tags and pigmented lesions.
Dr. Holcomb continued, "With the safety of the eCO2 micro-fractional laser, optimization of treatment protocols for off-face skin tightening and rejuvenation will be an area of intense interest."
Lutronic Corporation is a leading developer and manufacturer of medical laser systems serving the dermatological and plastic surgery communities. With distribution in over 40 countries and over a decade of award-winning technology design that includes its Spectra line of products and its unparalleled MOSAIC fractional systems, the company is committed to delivering innovative, highly effective, and painless laser solutions.
Lutronic continues to offer impressive customer service and support to
physicians and other qualified practitioners across the U.S. and globally.
To learn more about the eCO2, please visit http://www.lutronic.com.
Director, Marketing & Public Relations
Phone: 609 275-1565 x302 or 888 588-7644
Fax: 609 275-3800
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Lutronic, Inc.|
Copyright©2008 PR Newswire.
All rights reserved